Skip to content
Allegro Ophthalmics - From Theory to Therapy
  • About
    • Company
    • Management
    • Board of Directors
    • Scientific Advisors
  • Science
  • Pipeline
    • Pipeline
    • Risuteganib
    • ALG-1007
    • Clinical Trials
  • Therapeutic Areas
    • Dry AMD
    • Dry Eye Disease
  • News
    • Press Releases
    • Allegro in the News
    • Events

“BLOG: Still Much Progress Ahead in Retina”

Posted on February 14, 2017 | by Allegro Ophthalmics, LLC

John A. Hovanesian, MD, FACS, focuses his blog on new technologies and innovations and how ophthalmic practices can best incorporate them to benefit patients

To read the article, please visit Ocular Surgery News: “BLOG: Still Much Progress Ahead in Retina”

Posted in News Features
Allegro Ophthalmics - From Theory to Therapy

Setting the pace in ocular care
Read More >

Allegro Ophthalmics LLC
31473 Rancho Viejo Road, Suite 207
San Juan Capistrano, CA 92675, USA

Phone: +1 949.940.8130
Email: info@allegroeye.com

RECENT NEWS

Allegro Ophthalmics Licensee AffaMed Therapeutics Receives Phase 3 CTA Approval in China for Risuteganib for the Treatment of Intermediate Dry AMD
September 25, 2023

Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD
April 13, 2023

  • About
  • Science
  • Pipeline
  • Therapeutic Areas
  • News
  • Careers
  • Contact Us
© 2025 Allegro Ophthalmics, LLC. All rights reserved. | Privacy Policy | Terms of Use